Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review
Massimo Breccia, Matteo Molica, Giuliana Alimena
Leukemia Research (2014) Vol. 38, Iss. 12, pp. 1392-1398
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Yi Zhu, Tamar Tchkonia, Tamar Pirtskhalava, et al.
Aging Cell (2015) Vol. 14, Iss. 4, pp. 644-658
Open Access | Times Cited: 1974
The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where
Ioannis S. Pateras, Sophia Havaki, Xenia Nikitopoulou, et al.
Pharmacology & Therapeutics (2015) Vol. 154, pp. 36-56
Open Access | Times Cited: 132
DIAGNOSIS OF ENDOCRINE DISEASE: Endocrine late-effects of childhood cancer and its treatments
Wassim Chemaitilly, Laurie E. Cohen
European Journal of Endocrinology (2017) Vol. 176, Iss. 4, pp. R183-R203
Open Access | Times Cited: 79
Adipose Tissue Senescence and Inflammation in Aging is Reversed by the Young Milieu
Amiya K. Ghosh, Martin O’Brien, Theresa Mau, et al.
The Journals of Gerontology Series A (2018) Vol. 74, Iss. 11, pp. 1709-1715
Open Access | Times Cited: 67
Therapeutic Potential of Senolytics in Cardiovascular Disease
Emily Dookun, João F. Passos, Helen M. Arthur, et al.
Cardiovascular Drugs and Therapy (2020) Vol. 36, Iss. 1, pp. 187-196
Open Access | Times Cited: 54
Regulation of Cellular Senescence in Type 2 Diabetes Mellitus: From Mechanisms to Clinical Applications
Kanako Iwasaki, Cristian Abarca, Cristina Aguayo‐Mazzucato
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 4, pp. 441-453
Open Access | Times Cited: 19
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Oncotarget (2015) Vol. 6, Iss. 32, pp. 33944-33951
Open Access | Times Cited: 61
Mechanisms of cellular senescence-induced vascular aging: evidence of senotherapeutic strategies
Sophia Mahoney, Samuel I. Bloom, Douglas R. Seals, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Chronic myeloid leukemia: Second‐line drugs of choice
Carlo Gambacorti‐Passerini, Andrea Aroldi, Nicoletta Cordani, et al.
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 67-75
Open Access | Times Cited: 37
Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)
Sabina Sheppard‐Olivares, Nora M. Bello, Chad M. Johannes, et al.
Vet record open (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 18
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US
Meg Franklin, Leah Burns, Samuel Perez, et al.
Current Medical Research and Opinion (2017) Vol. 34, Iss. 2, pp. 353-360
Closed Access | Times Cited: 30
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper
Nicola Silvestris, Tindara Franchina, Marco Gallo, et al.
ESMO Open (2023) Vol. 8, Iss. 6, pp. 102062-102062
Open Access | Times Cited: 8
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 26
Antidiabetic Effects of the Senolytic Agent Dasatinib
Omid Salaami, Chia‐Ling Kuo, Matthew T. Drake, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 12, pp. 3021-3029
Open Access | Times Cited: 19
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
Annalisa Natalicchio, Antongiulio Faggiano, Maria Chiara Zatelli, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 169, pp. 103572-103572
Closed Access | Times Cited: 19
The role of AP-1 and epigenetics in ALCL
Lukas Kenner
Frontiers in Bioscience-Scholar (2015) Vol. 7, Iss. 2, pp. 226-235
Closed Access | Times Cited: 24
Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors
Melinda Wu, Javid J. Moslehi, Jonathan R. Lindner
Arteriosclerosis Thrombosis and Vascular Biology (2020) Vol. 41, Iss. 1, pp. 3-10
Open Access | Times Cited: 20
The Emerging Role of p21 in Diabetes and Related Metabolic Disorders
Omar Elmitwalli, Radwan Darwish, Lana Al-Jabery, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 13209-13209
Open Access | Times Cited: 2
The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion
Wei Du, Surya Amarachintha, Andrew F. Wilson, et al.
Leukemia (2016) Vol. 31, Iss. 2, pp. 423-433
Open Access | Times Cited: 15
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
Zeng Wang, Liyu Jiang, Hao Yan, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 4, pp. 445-456
Closed Access | Times Cited: 14
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
Nicola Silvestris, Antonella Argentiero, Giordano Beretta, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 154, pp. 103066-103066
Open Access | Times Cited: 13
Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells
Zhongling Zhu, Shan Xu, Jing Ren, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 4
The safety of Bosutinib for the treatment of chronic myeloid leukemia
Jee Hyun Kong, HJ Khoury, Audrey Sunwha Kim, et al.
Expert Opinion on Drug Safety (2017) Vol. 16, Iss. 10, pp. 1203-1209
Closed Access | Times Cited: 12
Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma
Mikhail Burmakin, Tijs van Wieringen, P. Olof Olsson, et al.
Journal of Translational Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top